Valence 로고
인기
로그인

관심목록에 추가
Pro 차트

First Trust NYSE Arca Bio...

NYSEArca: FBT · 실시간 가격 · USD
255.42
-0.65 (-0.25%)
종가 기준: Aug 14, 2026, 3:50 PM
255.28
-0.05%
애프터마켓: 7:34 PM

First Trust NYSE Arca Biotechnology Index Fund (FBT) Stock Price, Analysis & Data

-0.25%
매수호가255.13
시가총액n/a
매출 (ttm)n/a
순이익 (ttm)n/a
베타n/a
EPS (ttm)n/a
P/E (ttm)27.4
선행 P/En/a
P/B (ttm)1.48
P/S (ttm)n/a
Earnings Daten/a
매도호가255.31
거래량41,182
평균 거래량 (20일)65,724
시가255.00
전일 종가256.07
일중 범위253.31 - 255.57
52주 범위171.00 - 260.46
애널리스트n/a
목표주가n/a
배당n/a
배당락일n/a

FBT 소개

The fund will normally invest at least 90% of its net assets (including investment borrowings) in the securities that comprise the index. The index is an equal-dollar weighted index designed to measure the performance of 30 leading biotechnology companies....

[더 보기]
산업 n/a
섹터 n/a
IPO 일자 Jun 23, 2006
직원 수 n/a
상장 거래소 NYSEArca
티커 FBT
전체 기업 정보

재무 실적

undefined년 First Trust NYSE Arca Biotechnology Index Fund의 매출은 n/a로, 전년 n/a 대비 undefined% 증가했습니다. 순이익은 n/a로, undefined% 증가했습니다.

재무제표
news image

2주 전 · 24/7 Wall St.

FBT and IBB Are Not the Same Biotech Bet, and 5 Years of Returns Prove It

Most biotech investors treat FBT and IBB as two names for the same trade, but the structural differences buried in their index methodologies have produced shockingly different outcomes depending on wh...

news image

1개월 전 · Zacks

Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?

Smart Beta ETF report for FBT

news image

1개월 전 · Zacks

Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?

Sector ETF report for FBT

news image

7개월 전 · 24/7 Wall St.

Biotech Could Be One of 2026’s Biggest Winners, and This ETF Is Perfectly Positioned

Biotech investors spent years waiting for the sector to recover from its brutal 2021 peak. That patience is finally paying off. First Trust NYSE Arca Biotechnology Index Fund (NYSEARCA:FBT) has surged...

news image

8개월 전 · Zacks

Inside the Recent Strength in Biotech ETFs

Biotech strength is back, with IBB, PBE, FBT, CANC and HELX climbing as cheaper valuations, rate-cut hopes, FDA approvals and strong deal activity fuel biotech gains.

2 페이지 중 1